可溶性程序性死亡配体1可预测接受纳武利尤单抗治疗的胃癌患者预后:DELIVER试验的血液生物标志物分析
DELIVER试验纳入439例接受纳武利尤单抗单药治疗的胃癌患者,治疗前检测血浆sPD-1、sPD-L1、sCTLA-4。sPD-1、sPD-L1、sCTLA-4升高均与总生存缩短相关,仅sPD-L1升高与无进展生存缩短相关;sPD-L1与格拉斯哥预后评分(GPS)联合可提高预后判断准确性。
要点
- sPD-L1、sPD-1、sCTLA-4升高均与总生存缩短显著相关,仅sPD-L1与无进展生存缩短显著相关。
- sPD-L1与GPS均独立关联总生存,GPS 0且sPD-L1低者中位总生存最长(12.0个月)。
- GPS 2且sPD-L1高者中位总生存最短(3.1个月),与GPS 0且sPD-L1低者相比HR为3.69。
核心结论
- 基线sPD-L1水平有潜力预测接受纳武利尤单抗治疗的晚期胃癌患者的生存,与GPS联合可提高sPD-L1的预后判断准确性。
研究设计与样本
- DELIVER(日本临床癌症研究组织GC-08)试验的血液生物标志物分析,纳入439例接受纳武利尤单抗单药治疗的胃癌患者,检测治疗前血浆sPD-1、sPD-L1和sCTLA-4,并采集基线临床数据。
主要发现
- 血浆sPD-1升高与总生存缩短显著相关(HR=1.27,p=0.020)。
- 血浆sPD-L1升高与总生存缩短显著相关(HR=1.86,p<0.001)。
- 血浆sCTLA-4升高与总生存缩短显著相关(HR=1.33,p=0.008)。
- 仅sPD-L1升高与无进展生存缩短显著相关(HR=1.30,p=0.008)。
- sPD-L1浓度与GPS显著相关(p<0.001);sPD-L1(HR=1.67,p<0.001)与GPS均独立关联总生存(GPS 0 vs 1:HR=1.39,p=0.009;GPS 0 vs 2:HR=1.95,p<0.001)。
关键数值与推荐
- GPS 0且sPD-L1低的患者中位总生存最长,为12.0个月。
- GPS 2且sPD-L1高的患者中位总生存最短,为3.1个月。
- GPS 2且sPD-L1高者与GPS 0且sPD-L1低者相比,HR=3.69(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical value of soluble forms of programmed cell death-1 (sPD-1), PD ligand 1 (sPD-L1) and cytotoxic T lymphocyte-associated protein-4 (sCTLA-4) for gastric cancer (GC) patients treated with nivolumab monotherapy has remained unknown. METHODS: Blood samples collected before nivolumab treatment from 439 GC patients enrolled in the DELIVER (Japan Clinical Cancer Research Organisation GC-08) trial were analysed for sPD-1, sPD-L1 and sCTLA-4. Corresponding baseline clinical data were also retrieved. RESULTS: Higher plasma levels of sPD-1 (hazard ratio [HR] = 1.27, p = 0.020), sPD-L1 (HR = 1.86, p < 0.001) and sCTLA-4 (HR = 1.33, p = 0.008) were significantly associated with shorter overall survival (OS), whereas only higher sPD-L1 levels was significantly associated with shorter progression-free survival (HR = 1.30, p = 0.008). The sPD-L1 concentration was significantly associated with the Glasgow prognostic score (GPS) (p < 0.001), but both sPD-L1 (HR = 1.67, p < 0.001) and GPS (HR = 1.39, p = 0.009 for GPS 0 versus 1; HR = 1.95, p < 0.001 for GPS 0 versus 2) were independently associated with OS. Patients with a GPS of 0 and low sPD-L1 thus showed the longest OS (median, 12.0 months) and those with a GPS of 2 and high sPD-L1 showed the shortest OS (median, 3.1 months), yielding a HR of 3.69 (p < 0.001). CONCLUSION: Baseline sPD-L1 levels have the potential to predict survival for advanced GC patients treated with nivolumab, with the prognostic accuracy of sPD-L1 being improved by its combination with GPS.
引用
- Kawakami H, Sunakawa Y, Inoue E, et al. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial. Eur J Cancer. 2023. PMID: 36889037. doi:10.1016/j.ejca.2023.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。